Roth MKM analyst Boobalan Pachaiyappan initiated coverage of Gain Therapeutics (GANX) with a Buy rating and $7 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GANX: